218 related articles for article (PubMed ID: 32457102)
1. Genetic activation of Nrf2 reduces cutaneous symptoms in a murine model of Netherton syndrome.
Muzumdar S; Koch M; Hiebert H; Bapst A; Gravina A; Bloch W; Beer HD; Werner S; Schäfer M
Dis Model Mech; 2020 Jun; 13(5):. PubMed ID: 32457102
[TBL] [Abstract][Full Text] [Related]
2. A proinflammatory role of KLK6 protease in Netherton syndrome.
Zingkou E; Pampalakis G; Charla E; Nauroy P; Kiritsi D; Sotiropoulou G
J Dermatol Sci; 2019 Jul; 95(1):28-35. PubMed ID: 31255470
[TBL] [Abstract][Full Text] [Related]
3. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome.
Zingkou E; Pampalakis G; Sotiropoulou G
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165831. PubMed ID: 32442469
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a mouse model of Netherton syndrome based on CRISPR/Cas9 technology.
Guo JZ; Su J; Dai H; Wang XY; Wu WB; Chen T; Zhang J; Wang WH
Eur J Dermatol; 2022 Jul; 32(4):459-463. PubMed ID: 36301754
[TBL] [Abstract][Full Text] [Related]
5. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
[TBL] [Abstract][Full Text] [Related]
6. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.
Briot A; Deraison C; Lacroix M; Bonnart C; Robin A; Besson C; Dubus P; Hovnanian A
J Exp Med; 2009 May; 206(5):1135-47. PubMed ID: 19414552
[TBL] [Abstract][Full Text] [Related]
7. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
8. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model.
Briot A; Lacroix M; Robin A; Steinhoff M; Deraison C; Hovnanian A
J Invest Dermatol; 2010 Dec; 130(12):2736-42. PubMed ID: 20703245
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
Sugimoto S; Morizane S; Nomura H; Kobashi M; Sugihara S; Iwatsuki K
J Dermatol Sci; 2018 Nov; 92(2):181-187. PubMed ID: 30270115
[TBL] [Abstract][Full Text] [Related]
10. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.
Hovnanian A
Cell Tissue Res; 2013 Feb; 351(2):289-300. PubMed ID: 23344365
[TBL] [Abstract][Full Text] [Related]
11. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides.
Komatsu N; Takata M; Otsuki N; Ohka R; Amano O; Takehara K; Saijoh K
J Invest Dermatol; 2002 Mar; 118(3):436-43. PubMed ID: 11874482
[TBL] [Abstract][Full Text] [Related]
12. Transgenic Kallikrein 14 Mice Display Major Hair Shaft Defects Associated with Desmoglein 3 and 4 Degradation, Abnormal Epidermal Differentiation, and IL-36 Signature.
Gouin O; Barbieux C; Leturcq F; Bonnet des Claustres M; Petrova E; Hovnanian A
J Invest Dermatol; 2020 Jun; 140(6):1184-1194. PubMed ID: 32169475
[TBL] [Abstract][Full Text] [Related]
13. Physiological and pathological roles of kallikrein-related peptidases in the epidermis.
Kishibe M
J Dermatol Sci; 2019 Aug; 95(2):50-55. PubMed ID: 31279501
[TBL] [Abstract][Full Text] [Related]
14. Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial.
Di WL; Lwin SM; Petrova A; Bernadis C; Syed F; Farzaneh F; Moulding D; Martinez AE; Sebire NJ; Rampling D; Virasami A; Zamiri M; Wang W; Hara H; Kadiyirire T; Abdul-Wahab A; Martinez-Queipo M; Harper JI; McGrath JA; Thrasher AJ; Mellerio JE; Qasim W
Hum Gene Ther; 2019 Sep; 30(9):1067-1078. PubMed ID: 31288584
[TBL] [Abstract][Full Text] [Related]
15. Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy.
Furio L; Hovnanian A
Biol Chem; 2014 Sep; 395(9):945-58. PubMed ID: 25153381
[TBL] [Abstract][Full Text] [Related]
16. Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome.
Sales KU; Masedunskas A; Bey AL; Rasmussen AL; Weigert R; List K; Szabo R; Overbeek PA; Bugge TH
Nat Genet; 2010 Aug; 42(8):676-83. PubMed ID: 20657595
[TBL] [Abstract][Full Text] [Related]
17. Comparative analyses of Netherton syndrome patients and Spink5 conditional knock-out mice uncover disease-relevant pathways.
Petrova E; López-Gay JM; Fahrner M; Leturcq F; de Villartay JP; Barbieux C; Gonschorek P; Tsoi LC; Gudjonsson JE; Schilling O; Hovnanian A
Commun Biol; 2024 Feb; 7(1):152. PubMed ID: 38316920
[TBL] [Abstract][Full Text] [Related]
18. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
Furio L; de Veer S; Jaillet M; Briot A; Robin A; Deraison C; Hovnanian A
J Exp Med; 2014 Mar; 211(3):499-513. PubMed ID: 24534191
[TBL] [Abstract][Full Text] [Related]
19. Two siblings affected by Netherton/Comèl syndrome. Diagnostic pathology and description of a new SPINK5 variant.
Schepis C; Siragusa M; Centofanti A; Vinci M; Calì F
Dermatol Online J; 2019 Jul; 25(7):. PubMed ID: 31450277
[TBL] [Abstract][Full Text] [Related]
20. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis.
Chavarria-Smith J; Chiu CPC; Jackman JK; Yin J; Zhang J; Hackney JA; Lin WY; Tyagi T; Sun Y; Tao J; Dunlap D; Morton WD; Ghodge SV; Maun HR; Li H; Hernandez-Barry H; Loyet KM; Chen E; Liu J; Tam C; Yaspan BL; Cai H; Balazs M; Arron JR; Li J; Wittwer AJ; Pappu R; Austin CD; Lee WP; Lazarus RA; Sudhamsu J; Koerber JT; Yi T
Sci Transl Med; 2022 Dec; 14(675):eabp9159. PubMed ID: 36516271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
